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The volume of shoulder arthroplasty surgery is increasing, and 
with it the expectation of future revision surgery (Lübbeke et 
al. 2017, AOANJRR 2019). The survivorship for anatomic 
shoulder arthroplasty has been well documented (Singh et al. 
2011, Page et al. 2014, 2018, Dillon et al. 2019). Previously, 
revising anatomic shoulder arthroplasty often necessitated 
bone grafting and re-cementing of the glenoid component. 
This was associated with soft tissue failure and graft reabsorp-
tion (Scalise and Iannotti 2008). Reverse total shoulder arthro-
plasty (rTSA) offered an opportunity to solve some of these 
problems (Boileau et al. 2006). Early reports indicated a high 
complication rate, but satisfactory clinical outcomes (Melis et 
al. 2012). 
The outcome of lower limb revision arthroplasty has dem-
onstrated higher subsequent revision rates compared with 
known primary procedures (AOANJRR 2018). Similar analy-
sis for shoulder arthroplasty has been more limited, concen-
trating on specific component revisions or technical descrip-
tions (Cheung et al. 2008, Scalise and Iannotti 2008, Melis et 
al. 2012, Bonnevialle et al. 2013). These studies have been 
on small numbers and of short duration. A larger population-
based study enables new insights, with a larger number of 
revision arthroplasty procedures for analysis.
The Australian Orthopaedic Association National Joint 
Replacement Registry (AOANJRR) has a high enrolment 
rate. This allows the opportunity to accurately plot popula-
tion-based shoulder arthroplasty outcomes based on a large 
volume of implants and across a broad range of diagnoses and 
surgeons.
This study determined the rate of (second) revision follow-
ing aseptic first revision shoulder arthroplasty, taking into 
account the type of primary shoulder arthroplasty revised, and 
the class of revision undertaken.
Background and purpose — The increase in shoulder 
arthroplasty may lead to a burden of revision surgery. This 
study compared the rate of (2nd) revision following aseptic 
1st revision shoulder arthroplasty, considering the type of 
primary, and the class and type of the revision.
Patients and methods — All aseptic 1st revisions of 
primary total reverse shoulder arthroplasty (rTSA group) 
and of primary total stemmed and stemless total shoulder 
arthroplasty (non-rTSA group) procedures reported to our 
national registry between April 2004 to December 2018 were 
included. The rate of 2nd revision was determined using 
Kaplan–Meier estimates and comparisons were made using 
Cox proportional hazards models.
Results — There was an increased risk of 2nd revision in 
the 1st month only for the rTSA group (n = 700) compared 
with the non-rTSA group (n = 991); hazard ratio (HR) = 4.8 
(95% CI 2.2–9). The cumulative percentage of 2nd revisions 
(CPR) was 24% in the rTSA group and 20% in the non-rTSA 
group at 8 years. There was an increased risk of 2nd revision 
for the type (cup vs. head) HR = 2.2 (CI 1.2–4.2), but not 
class of revision for the rTSA group. Minor (> 3 months) 
vs. major class revision, and humeral revision vs. all other 
revision types were second revision risk factors for the non-
rTSA group.
Interpretation — The CPR of revision shoulder arthro-
plasty was > 20% at 8 years and was influenced by the type 
of primary, the class, and the type of revision. The most 
common reasons for 2nd revision were instability/disloca-
tion, loosening, and infection.
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Patients and methods
The AOANJRR began data collection on September 1, 1999 
and includes data on almost 100% of the hip and knee arthro-
plasty procedures performed in Australia since 2002. Data 
collection was expanded to include shoulder arthroplasty pro-
cedures in April 2004 and has documented 97.1% shoulder 
arthroplasty procedures Australia-wide since November 2007. 
These data are externally validated against patient-level data 
provided by all Australian state and territory health depart-
ments. A sequential, multilevel matching process is used to 
identify any missing data, which are subsequently obtained 
by follow-up with the relevant hospital. Each month, in addi-
tion to internal validation and data quality checks, all primary 
procedures are linked to any subsequent revision involving the 
same patient, joint, and side. Data are also matched bi-annu-
ally to the Australian National Death Index data to identify 
patients who have died. 
In this study, the 1st revisions of primary total reverse shoul-
der arthroplasty (rTSA group) and total stemmed and stem-
less (non-rTSA group) procedures performed between April 
16, 2004 and December 31, 2018 were analyzed. Resurfac-
ing arthroplasty and hemiarthroplasty were excluded. Revi-
sion was defined as removal/exchange or addition of a joint 
replacement implant. The type of shoulder arthroplasty was 
the description of the implant (e.g., rTSA or non-rTSA) and 
the type of revision was the specifically removed/exchanged 
component (e.g., glenoid articular insert). Revision was fur-
ther categorized as minor or major. A minor revision involved 
an exchange of implant not fixed to bone. A major revision 
involved an exchange of a component with bone fixation on 
both the glenoid and humeral sides, whilst a partial major revi-
sion exchanged bone-fixed components on either the glenoid 
or humeral side exclusively. A humeral revision included either 
metaphyseal or both metaphyseal and diaphyseal components. 
All 1st revisions for infection were excluded to remove the 
confounding effect on subsequent revisions. The outcome 
measure was time to 2nd revision for all diagnoses including 
infection to capture all subsequent revision endpoints. 
Statistics
Kaplan–Meier estimates of survivorship were used to report 
the time to second revision, with censoring at the time of 
death and closure of the dataset at the end of December 2018. 
The unadjusted cumulative percentage revisions (CPRs), 
with 95% confidence intervals (CI), were calculated using 
unadjusted point-wise Greenwood estimates. The CPR is 
displayed until the number at risk for the group reaches 40, 
unless the initial number for the group is less than 100, in 
which case the cumulative percentage revision is reported 
until 10% of the initial number at risk remains. Age- and sex-
adjusted hazard ratios (HR) were calculated from Cox pro-
portional hazard models to compare the rate of second revi-
sion between groups. The assumption of proportional hazards 
was checked analytically for each model. If the interaction 
between the predictor and the log of time was statistically 
significant in the standard Cox model, then a time-varying 
model was estimated. Time points were selected based on the 
greatest change in hazard, weighted by a function of events. 
Time points were iteratively chosen until the assumption of 
proportionality was met and HRs were calculated for each 
selected time-period. For the current study, if no time-period 
was specified, the HR was calculated over the entire follow-
up period. All tests were 2-tailed at 5% levels of significance. 
Statistical analysis was performed using SAS software ver-
sion 9.4 (SAS Institute Inc., Cary, NC, USA).
Ethics, funding, and potential conflicts of interest
The AOANJRR is approved by the Australian Federal Gov-
ernment as a federal quality assurance activity under Section 
124X of the Australian Federal Health Insurance Act 1973. 
All investigations were conducted in accordance with the 
ethical principles of research (The Helsinki Declaration II). 
The AOANJRR is funded by the Commonwealth of Australia 
Department of Health and Ageing. The data of the AOAN-
JRR is the intellectual property of the Australian Orthopaedic 
Association. The authors declare no financial disclosures.
Results
There were 1,845 1st revisions of primary total shoulder 
arthroplasty, with 154 excluded as septic 1st revisions during 
the study period. Of those remaining, 41% (n = 700) were in 
the rTSA group, and 59% (n = 991) were in the non-rTSA 
group. Among the rTSA group 96% (n = 258) remained 
reverse shoulder arthroplasty at revision and 83% (n = 710) 
of the non-rTSA group were converted to a reverse shoulder 
arthroplasty at revision. There were 429 minor revisions, 232 
were partial major, and 39 were major in the rTSA group. In 
the non-rTSA group 128 were minor, 621 were partial major, 
and 242 were major. Amongst the rTSA group the revisions by 
type were 270 head/cup, head only, or cup only, 64 glenoid, 
166 humeral, and 39 humeral/glenoid. In the non-rTSA group 
123 humeral head/glenoid insert or humeral head only, 66 
glenoid, 553 humeral, and 242 humeral/glenoid components 
were revised (Table 1).
For 1st revision shoulder arthroplasty, the mean age of 
patients in the rTSA group was 73 years (72 years for males 
and 73 years for females) and 52% of patients were female. 
Patients in the non-rTSA group had a mean age of 67 years (65 
years for males and 69 years for females) and 60% of patients 
were female (Table 1). 
2nd revisions were undertaken in 18% (n = 129) of the rTSA 
group and in 16% (n = 157) of the non-rTSA group (Table 1). 
In the rTSA group, the CPR at 1 year was 13% and at 8 years it 
was 24%. In the non-rTSA group, the 1-year CPR was 9% and 
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major compared with partial major classes of revision (HR 
1.9; CI 1.2–2.9) (Figure 2). 
The type of revision was a statistically significant risk of 
2nd revision of cup only compared with head only for the 
rTSA group (entire period: HR  2.2; CI 1.2–4.2). Other types 
of revision were not 2nd revision risks. However, humeral 
head/glenoid insert (after 3 months), humeral head only, gle-
noid, and glenoid/humeral revision were risk factors for 2nd 
revision compared with humeral component revision for the 
non-rTSA group (Figure 3). 
The distribution of patients from the rTSA group and 
the non-rTSA group at 2nd revision by 4 age categories is 
recorded in Table 1. There was an increased risk of a 2nd revi-
sion for patients aged 65–74 years in the rTSA group com-
pared with the non-rTSA group (HR 1.5; CI 1.0–2.1). Patients 
aged 55–64 years had an increased risk of a 2nd revision in the 
first 2 weeks in the rTSA group compared with the non-rTSA 
group (HR 16; CI 2–134), with no significant difference after 
this time. There was no statistically significant difference in 
the risk of 2nd revision in any other age group category over 
the entire period of the study.
The most common diagnosis of primary shoulder arthro-
plasty that underwent aseptic 1st revision was osteoarthritis, 
Table 1. Characteristics of rTSA group and non-rTSA group (all diagnoses, excluding 1st 
revision for infection)
 Non-rTSA group rTSA group
 2nd revisions 1st revisions 2nd revisions 1st revisions
 n = 157 (15.8%) n = 991  n = 129 (18.4%) n = 700  
Variable n (% of 1 st rev.) n (%) n (% of 1 st rev.) n (%)
Female sex  594 (59.9)  367 (52.4) 
Age     
 < 55 14 (18.7) 75 (7.6)  4 (19.0) 21 (3.0) 
 55–64 57 (20.2) 282 (28.5)  25 (27.2) 92 (13.1) 
 65–74 61 (15.0) 407 (41.1) 54 (19.4) 279 (39.9) 
 ≥ 75 25 (11.0) 227 (22.9) 46 (14.9) 308 (44.0)
Primary diagnosis a     
 Fracture 1 (5.9) 17 (1.7)  28 (25.0) 112 (16.9)
 Osteoarthritis 142 (15.4) 923 (94.6)  54 (19.2) 281 (42.4) 
 Osteonecrosis 5 (31.3) 16 (1.6) 0 (0.0) 6 (0.9) 
 Rheumatoid arthritis 2 (20.0) 10 (1.0)  3 (15.8) 19 (2.9) 
 Rotator cuff arthropathy 3 (30.0) 10 (1.0)  36 (14.7) 245 (37.0) 
Class of 1st revision     
 Minor 67 (52.3) 128 (12.9)  81 (18.9) 429 (61.3) 
 Major partial 56 (9.0) 621 (62.7) 40 (17.2) 232 (33.1) 
 Major total 34 (14.0) 242 (24.4)  8 (20.5) 39 (5.6) 
Type of 1st revision b     
 Head/insert revision c 25 (78.1) 32 (3.3) 0 (0.0) 1 (0.2) 
 Head only revision c 41 (45.1) 91 (9.2)  13 (10.7) 121 (22.4) 
 Cup only c   38 (25.7) 148 (27.5)  
 Humeral/glenoid revision 34 (14.0) 242 (24.6)  8 (20.5) 39 (7.2) 
 Glenoid component revision 13 (19.7) 66 (6.7) 13 (20.3) 64 (11.9) 
 Humeral component revision 43 (7.8) 553 (56.2)  27 (16.3) 166 (30.8) 
a Only the outcome of the 5 most common primary diagnoses have been included.
b Only the outcome of the six most common types of 1st revision have been listed.
c rTSA group head/insert  = glenosphere/humeral insert, head only  = glenosphere only, 
cup only = humeral insert only.
c non-rTSA group head/insert  = humeral head/glenoid insert, head only  = humeral head 
only, cup only  = N/A.
Table 2. Yearly cumulative percentage of 
second revision (CPR) of first revision groups 
rTSA and non-rTSA (all diagnoses, excluding 
1st revision for infection)
CPR (CI)  Non-rTSA
after years group rTSA group
  
 1 9.4 (7.7–11) 13 (11–16)
 2 14 (12–16) 16 (13–19)
 3 15 (13–18) 18 (15–21)
 4 16 (14–19) 20 (17–24)
 5 17 (14–20) 22 (19–26)
 6 19 (16–22)  23 (19–27)
 7 19 (16–22) 23 (19–27)
 8 20 (17–24) 24 (20–28)
 9 20 (17–24) –










Years since 1st revision
0 1 2 3 4 5 6 7 8 9 10
1st revision of primary rTSA
1st revision of primary non-rTSA
Number at risk
Follow-up years 0 1 2 3 4 5 6 7 8 9 10 11 12
1st revisions, n 
 non-rTSA 991 846 673 541 435 328 237 148 90 56 26 5 1
 rTSA 700 537 407 306 224 157 112 77 50 31 15 2 0
Figure 1. Cumulative percentage of 2nd revision of 1st revision groups 
rTSA and non-rTSA by type of primary (all diagnoses, excluding 1st 
revision for infection). 
HR (CI)—adjusted for age and sex 
1st revision of primary rTSA vs 1st revision of primary non-rTSA
   0–1 month    HR 4.8 (2.5–9.0)
   1–6 months  HR 1.1 (0.68–1.6)
   > 6 months   HR 1.2 (0.82–1.6)
at 8 years it was 20% (Table 2). There was 
a significantly higher rate of 2nd revisions 
in the rTSA group for the 1st month only 
(HR 4.8; CI 2.2–8.9) (Figure 1). After 1 
month, there was no significant difference 
in the risk of a 2nd revision. 
Analysis of the class of revision found 
no significant difference in the risk of a 
2nd revision for the rTSA group. How-
ever, for the non-rTSA group, there was 
an increased risk of a 2nd revision after 
3 months for the minor class compared 
with other classes of revision (p < 0.001) 
(Figure 1). The non-rTSA group also had 
an increased risk of a 2nd revision for total 
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with 54 of 281 in the rTSA group and 142 of 923 in the non-
rTSA group undergoing a 2nd revision (Table 1). Primary 
shoulder arthroplasty undertaken for osteoarthritis had a 
higher risk of a 2nd revision in the rTSA group compared with 
the non-rTSA group (HR 1.5; 1.1–2.1). There was insufficient 
data to determine whether the diagnoses of fracture, osteone-
crosis, rheumatoid arthritis, and rotator cuff arthropathy were 
risk factors for a 2nd revision.
The 3 most common reasons for 2nd revision were similar for 
both groups of 1st revision shoulder arthroplasty, but the per-
centages differed. The most common reason for 2nd revision 
was instability/dislocation and was highest for the rTSA group 
(54%) compared with the non-rTSA group (36%). There were 
equal numbers of revisions for loosening (16%) and infection 
(16%) for the rTSA group. For the non-rTSA group, 2nd revi-
sion for loosening was higher (20%) but for infection it was 
lower (12%) compared with the rTSA group. Collectively, the 
diagnoses of instability/dislocation, loosening, and infection 
accounted for 85% of 2nd revision procedures in the rTSA 
group, and 68% in the non-rTSA group (Table 3). During the 
1st month after revision the most common reason for a 2nd 









Years since 1st revision
0 1 2 3 4 5 6 7 8 9 10
Minor 1st revision of primary TSA
Major partial 1st revision of primary TSA
Major total 1st revision of primary TSA
Number at risk
Follow-up years 0 1 2 3 4 5 6 7 8 9 10 11 12
Non-rTSA group, n 
 minor 128 90 66 53 41 31 22 17 10 5 3 1 0
 major partial 621 562 471 399 327 247 180 111 68 45 19 4 1
 major total 242 194 136 89 67 50 35 20 12 6 4 0 0
Number at risk
Follow-up years 0 1 2 3 4 5 6 7 8 9 10 11 12
Non-rTSA group, n 
 humeral head/
 glenoid insert  32 19 10 7 5 3 2 2 1 0 0 0 0
 humeral head only  91 67 52 44 34 27 19 14 8 4 2 1 0
 humeral/glenoid  242 194 136 89 67 50 35 20 12 6 4 0 0
 glenoid comp.  66 58 49 46 39 28 21 16 12 10 7 1 1
 humeral comp.  553 502 421 352 287 218 158 94 55 34 12 3 0
Figure 2. Cumulative percentage of second revision of first revision 
group non-rTSA by class of the first revision (all diagnoses, excluding 
first revision for infection).
HR (CI)—adjusted for age and sex
Non-rTSA group minor revision vs. non-rTSA group major partial 
revision
   0–3 months  HR 2.1 (0.95–4.7)
   3 months–2 years  HR 9.7 (6.1–15)
   > 2 years  HR 9.7 (4.6–20)
Non-rTSA group minor revision vs. non-rTSA group major total revision
   0–3 months  HR 1.1 (0.50–2.6)
   3 months–1.5 years  HR 5.3 (3.1–9.0)
   1.5 years–2 years  HR 4.8 (1.8–13)
   > 2 years  HR 5.2 (2.4–12),
Non-rTSA group major total revision vs. non-rTSA group major partial 
revision
   Entire period  HR 1.9 (1.2–2.9)
Figure 3. Cumulative percentage of second revision of first revision 
group non-rTSA by type of revision (all diagnoses, excluding revision 
for infection).
HR (CI)—adjusted for age and sex
Humeral head/glenoid insert revision vs. humeral component revision
   0–3 months HR = 3.2 (0.74–13)
   3 months–1.5 years HR = 15 (7.7–29)
   > 1.5 years  HR = 34 (16–72)
Humeral head only revision vs. humeral component revision
   Entire period HR = 6.8 (4.4–10)
Humeral/glenoid revision vs. humeral component revision
   Entire period HR = 2.2 (1.4–3.4)
Glenoid component revision vs. humeral component revision
   Entire period HR = 2.5 (1.3–4.6)
Table 3. 2nd revision diagnosis of first revision groups rTSA and 
non-rTSA (all diagnoses excluding 1st revision for infection)
 Non-rTSA group rTSA group
  2nd rev. % of 1st 2nd rev. % of 1st
  n = 157 revisions n = 129 revisions
2nd revision diagnosis n (%) n = 991 n (%) n = 700
Instability/dislocation 57 (36.3) 5.8 70 (54.3) 10.0
Loosening 31 (19.7) 3.1 20 (15.5) 2.9
Infection 18 (11.5) 1.8 20 (15.5) 2.9
Rotator cuff insufficiency 14 (8.9) 1.4 1 (0.8) 0.1
Fracture 4 (2.5) 0.4 6 (4.7) 0.9
Implant breakage 
 glenoid insert  6 (3.8) 0.6 1 (0.8) 0.1
Pain  5 (3.2) 0.5 1 (0.8) 0.1
Dissociation  4 (2.5) 0.4  
Implant breakage glenoid  2 (1.3) 0.2  
Malposition  2 (1.3) 0.2 1 (0.8) 0.1
Metal related pathology  2 (1.3) 0.2  
Arthrofibrosis   1 (0.8) 0.1
Implant breakage humeral  1 (0.6) 0.1 1 (0.8) 0.1
Wear glenoid  1 (0.6) 0.1  
Wear glenoid insert  1 (0.6) 0.1  
Wear humeral cup  1 (0.6) 0.1 1 (0.8) 0.1
Other  8 (5.1) 0.8 6 (4.7) 0.9
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revision for both the rTSA group (80%) and the non-rTSA 
group (62%) was instability/dislocation. 
Discussion
The AOANJRR (2018) reported the CPR of primary total 
shoulder arthroplasty. By comparison, this study found the 
CPR of first revisions of primary rTSA and non-rTSA to be 2 
to 3 times higher at 12 months, and then at year 8 greater than 
20%. We are not aware of any large patient study that previ-
ously indicated such an increase in CPR for revision shoulder 
arthroplasty. Others have also reported the outcome of primary 
TSA and rTSA from the perspective of survivorship (Boileau 
et al. 2006, Singh et al. 2011, Craig et al. 2019). This study has 
indicated that, for both rTSA and non-rTSA, the survivorship 
of the primary was substantially higher than their comparable 
first revisions (AOANJRR 2018) despite our exclusion of septic 
1st revisions. We suggest that studies such as ours serve as a 
baseline that future revision methods look to and improve upon. 
Craig et al. (2019) examined revisions and reoperations in 
a population-based study of 58,054 primary shoulder arthro-
plasty procedures and reported similar demographics, but also 
a high number of non-implant reoperations for primary shoul-
der arthroplasty. Our study highlights the high 2nd revision 
rate of shoulder arthroplasty looking exclusively at implant 
exchange. Both studies confirm the increased operative burden 
that occurs with shoulder arthroplasty. 
There was a statistically significant increase in risk of 
second revision in the 1st month after the revised primary 
rTSA over non-rTSA. Our study showed the most common 
reason for 2nd revision in that period was dislocation/instabil-
ity. We did not identify specific early (under 1 month) risk fac-
tors of second revision on comparing the 2 cohort groups by 
class or type of revision. It has been previously reported that 
revision of rTSA is difficult, with a complication rate ranging 
from 11% to 36% (Sajadi et al. 2010, Austin et al. 2011, Kelly 
et al. 2012, Patel et al. 2012, Wagner et al. 2018). We confirm 
that, and the temporal nature of those difficulties. It is likely 
that the high conversion to reverse shoulder arthroplasty of 
primary non-rTSA led to the similar CPR results overall after 
1 month in this study for the 2 cohort groups. 
Our study indicates there would not be confidence in under-
taking minor procedures of first revision non-rTSA. Dines et al. 
(2006) reviewed the outcome of 78 shoulders that underwent 
revision. They reported component revision was superior to soft 
tissue revision surgery on the basis of clinical outcome. Their 
study concluded that glenoid revision had a lower rate of revi-
sion compared with other revision procedures. Our results sug-
gest that humeral cup revision has an increased 2nd revision risk. 
Whilst this may be confounded by diagnosis, there are other 
minor class revisions that are not 2nd revision risks, such as head 
revision. Given instability is a common reason for primary rTSA 
revision, we believe our study is consistent with the findings of 
Cheung et al. (2018). Cil et al. (2009) reviewed the outcome 
of 38 humeral revisions for aseptic loosening for total shoulder 
arthroplasty and hemiarthroplasty. This type of revision surgery 
gave reliable pain relief but at a high risk of intraoperative com-
plication, with 89% survivorship achieved at 10 years. 
There were no clear advantages between differing classes of 
1st revision rTSA in our study. Boileau et al. (2013) reported 
37 patients who underwent revision rTSA with 11 patients 
requiring 2nd revision surgery. Overall, 32 retained an rTSA 
at follow-up at 34 months. Black et al. (2015) reported on 16 
patients who underwent component revision after rTSA with 
a mean follow-up at 5 years. The study reported 6 of the 16 
patients underwent further surgery and 9 sustained major 
complications. There was an improvement in pain and func-
tional scores in their series.
Little is known about the 2nd revision outcome of shoulder 
arthroplasty. Zumstein et al. (2011) reported a 2nd revision 
rate of 16% for reverse replacements in a meta-analysis. In the 
study by Black et al. (2015), of the 6 rTSA revised for instabil-
ity 2 subsequently required resection arthroplasty and of the 
7 revised for glenoid baseplate failure 1 underwent resection 
arthroplasty. Our rates of 2nd revision were consistent with 
the combined series by Zumstein et al. (2011).
The diagnosis of osteoarthritis (when controlling for age 
and sex) was a risk factor for a 2nd revision of shoulder arthro-
plasty in our study. Singh et al. (2011) examined date of revi-
sion for total shoulder arthroplasty for 2,588 shoulders from 
1976 to 2008. They found that male sex and rotator cuff dis-
ease were independent risk factors for revision of total shoul-
der arthroplasty. We were only able to confirm younger age 
as a risk factor for a 2nd revision in the first 2 weeks after the 
primary shoulder arthroplasty was revised.
The indications for 2nd revisions of rTSA and non-rTSA 
reflect similar problems to those that occur with primary TSA 
and primary rTSA. Kelly et al. (2012) observed for reverse 
total shoulder failed arthroplasty that the indications for the 
procedure included cuff deficiency, glenoid bone loss, humeral 
bone loss, or instability of the primary arthroplasty. The Nor-
wegian Registry study of rTSA revisions found infection and 
loosening to be the most common diagnoses at revision sur-
gery (Fevang et al. 2009). Khan et al. (2009) reported that 
rotator cuff tears, especially in those with rheumatoid arthri-
tis, were the most common reason for cemented total shoulder 
arthroplasty revisions. 
There are limitations to this study. The differing methods of 
enrolment and reporting of statistical outcomes of joint regis-
tries limit the ability of comparison. The recorded diagnosis 
is based on a categorical hierarchy and only the primary diag-
nosis has been used in this study so there may be additional 
reasons for the revision contributing to revision. This study 
excluded all primary rTSA and non-rTSA revised for infec-
tion. The aseptic study population gave guidance regarding 
relative implant performance of the 2 cohort groups. Infection 
of primary shoulder arthroplasty may lead to more complex 
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revisions, a staged response with an outcome more related to 
the infection than the device. To ensure capture of all revi-
sion endpoints, 2nd revision for infection was included. The 
exclusion of 1st revision for infection, and those 1st revisions 
subsequently diagnosed as infective managed by antibiotic 
suppression, may confound infection as reason for 2nd revi-
sion. We examined survivorship outcomes measured on a 
population basis without seeking to select out variations due 
to implant type, patient selection, surgeons, or geography. 
This does not represent, necessarily, the optimum achievable 
results for any particular implant or procedure. This registry 
data did not include clinical recording such as VAS scores, 
strength, or range of motion. Similar survivorship may not 
necessarily imply similar outcomes for pain and function. 
Conclusions
A revised total shoulder arthroplasty has a greater than 20% 
risk of 2nd revision at 8 years. The type of primary was not a 
risk factor for a 2nd revision, except in the 1st month, where 
an rTSA was an increased risk for a 2nd revision compared 
with a non-rTSA. The risk of a 2nd revision was affected by 
type and class of the revision, patient age, and the primary 
diagnosis osteoarthritis when adjusted for sex. The most 
common reasons for undertaking a 2nd revision were instabil-
ity/dislocation, loosening, and infection.
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